LEAP2 and metabolic syndrome: Additional modulation may involve liver-expressed antimicrobial peptide 2 (LEAP-2), which could exacerbate ghrelin resistance due to its association with obesity and metabolic syndrome, both recognized AD risk factors [302,303].